Amylin Pharmaceuticals, Inc.

Other

Arena Pharmaceuticals, Inc.

Anji Pharma (us) LLC

Nigel R Beeley

Kathryn Susan Prickett

Andrew A Young

Derek T Chalmers

Chen Wang Liaw

Alain D Baron

Dominic P Behan

Mark S Fineman

Frédérique Menzaghi

Timothy J Rink

William J Thomsen

Joseph F Russo

Qian Liu

Julian R Smith

Robert C Glen

Richard J Foster

Michael S Lawless

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Biguanide compositions and methods of treating metabolic disorders

Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.

Exendin agonist peptides

Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT.sub.2A and human 5-HT.sub.2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT.sub.2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT.sub.2A receptors.

Small molecule modulators of non-endogenous, constitutively activated

Compounds of formula I which act as amylin agonists with respect to certain desired amylin activities and as calcitonin agonists with respect to certain desired calcitonin activities are provided. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including, but not limited to diabetes mellitus, including Type I diabetes and Type II diabetes. The present invention also relates to methods of treating Type I diabetes, treating Type II diabetes and to methods of beneficially regulating gastrointestinal motility comprising administration of a therapeutically effective among of one of the compounds. Also provided are pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier.

Anti-diabetic peptides

Compositions and methods for reducing food intake, suppressing appetite and controlling body weight are provided. Such compositions may include an amylin agonist and a CCK agonist or a hybrid peptide.

Appetite regulating compositions

Growing community of inventors

Solana Beach, CA, United States of America

Nigel R Beeley